






<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>					<b>SERIAL NO.</b> 10/529,922		
					<b>FILING DATE</b> March 30, 2005		
					<b>APPLICANT</b> BACUS et al.		
					<b>GROUP</b> 		
					<b>EXAMINER</b> 		
					<b>ATTORNEY DOCKET NO.</b> PU4995USw		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	1.	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	2003/0124130	7/3/2003	Brown			
	2.	2003/0152959	8/24/2003	Mertz et al.			
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	3.	2005/011607	2/10/2005	PCT			
	4.	2005/017493	2/24/2005	PCT			
	5.	2005/121380	12/22/2005	PCT			
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	6.	XIA et al., Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene 21:6255-6263 (2002).					
Continue on page _____							
<b>EXAMINER</b> 					<b>DATE CONSIDERED</b> 9/14/07		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

<b>SERIAL NO.</b>	<b>10/529,922</b>
<b>FILING DATE</b>	<b>March 30, 2005</b>
<b>APPLICANT</b>	<b>BACUS et al.</b>
<b>GROUP</b>	
<b>EXAMINER</b>	
<b>ATTORNEY DOCKET NO.</b>	<b>PU4995USw</b>

## U.S. PATENT DOCUMENTS

[illegible]

**Continue on page**

**FOREIGN PATENT DOCUMENTS**

[illegible]

Continue on page

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

2.	ALBANELL et al., Pharmacodynamic Studies with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839, <i>Seminars in Oncology</i> 28(5), Suppl 16:56-66 (2001).
3.	ALBANELL et al., Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor $\alpha$ Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments, <i>Cancer Research</i> 61:6500-6510 (2001).
4.	ANDERSON et al., ZD1839 (IRESSA), A Novel Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Potently Inhibits the Growth of EGFR-Positive Cancer Cell Lines With or Without ERBB2 Overexpression, <i>Int. J. Cancer</i> 94:774-782 (2001).
5.	FILARDO et al., Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF, <i>Molecular Endocrinology</i> 14(10):1649-1660 (2000).
6.	GEE et al., Phosphorylation of Erk1/2 Mitogen-Activated Protein Kinase is Associated with Poor Response to Anti-Hormonal Therapy and Decreased Patient Survival in Clinical Breast Cancer, <i>Int. J. Cancer</i> 95:247-254 (2001).
7.	PAWELETZ et al., Reverse Phase Protein Microarrays which Capture Disease Progression Show Activation of Pro-survival Pathways at the Cancer Invasion Front, <i>Oncogene</i> 20:1981-1989 (2001).
8.	RUSNAK et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>In Vitro</i> and <i>In Vivo</i> , <i>Molecular Cancer Therapeutics</i> 1:85-94 (2001).
9.	SOLORZANO et al., <i>In Vivo</i> Intracellular Signaling as a Marker of Antiangiogenic Activity, <i>Cancer Research</i> 61:7048-7051 (2001).

**Continue on page**

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.